




**FIG. 1**

| Subject ID    | CAR-T<br>(cell/ul)<br>Cmax | Day 28 | Day 42 | Day 56 | Day 78 | Day 100 |
|---------------|----------------------------|--------|--------|--------|--------|---------|
| L28US10003011 | 13805                      | 7135   | 5279   | 5957   | 2836   | 2464    |
| L28US10025003 | 6416                       | 4639   | 1426   | ND     | 798    | 1172    |
| L28US10017023 | 5523                       | 1736   | 1437   | 926    | 772    | 576     |
| L28US10024005 | 4320                       | 827    | 378    | 328    | 238    | 184     |
| L28US10007001 | 4053                       | ND     | 894    | 828    | 615    | 533     |
| L28US10002034 | 4024                       | 844    | 454    | 1277   | ND     | 1077    |
| L28US10007002 | 3092                       | 1767   | 1242   | 733    | 675    | ND      |
| L28US10002024 | 2890                       | 249    | 383    | 514    | 316    | ND      |
| L28US10002023 | 2876                       | 1826   | 1145   | 600    | ND     | 562     |
| L28US10001016 | 2846                       | 2614   | 2382   | 2534   | ND     | 1994    |
| L28US10002032 | 1636                       | 1146   | 595    | 610    | ND     | 100     |
| L28US10021007 | 1428                       | 586    | 248    | ND     | ND     | 303     |

FIG. 2




FIG. 3






FIG. 4

**FIG. 5**

**FIG. 6**







FIG. 7

**FIG. 8A**

**FIG. 8B**

**FIG. 8B (continued)**





FIG. 9

*FIG. 9 (continued)*

| Listing of Tumor Burden and Bridging Therapy; Subjects With Movement and Neurocognitive TEAEs; All Treated Analysis Set (Study 68284528MMY2001) |                                     |                                              |                                                      |                                                                 |                                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------|------------------------------------------|
| Subject ID                                                                                                                                      | Measurable Disease Type at Baseline | Clinical Tumor Burden Assessment at Baseline | SPD of EMP at Baseline if Present (mm <sup>3</sup> ) | Change in Tumor Burden from Screening to Cilia-Cel Infusion (%) | Bridging Therapy                         |
| L28US10002023                                                                                                                                   | Serum only                          | Low                                          | 2348                                                 | -60                                                             | BORTEZOMIB, MELPHALAN                    |
| L28US10003011                                                                                                                                   | Serum only                          | High                                         | .                                                    | Not evaluable                                                   | CARFILZOMIB, DEXAMETHASONE               |
| L28US10017023                                                                                                                                   | Serum only                          | High                                         | .                                                    | 50                                                              | DEXAMETHASONE                            |
| L28US10021005                                                                                                                                   | Serum only                          | Intermediate                                 | .                                                    | 14.3                                                            | DEXAMETHASONE                            |
| L28US10025003                                                                                                                                   | FLC                                 | High                                         | .                                                    | 50.1                                                            | DARATUMUMAB, DEXAMETHASONE, POMALIDOMIDE |

Key: EMP = extramedullary plasmacytoma, SPD = sum of product diameters.  
Note: High burden consists of subjects meeting any of the conditions: bone marrow plasma cell ≥ 30%, serum M-spike ≥ 5g/dL, serum free light chains ≥ 5000 mg/L. Low burden consists of subjects meeting all conditions available: bone marrow plasma cell < 50%, serum M-spike < 3g/dL, serum free light chains < 3000 mg/L. Intermediate burden includes subject not meeting High nor Low burden criteria.  
Note: Disease burden represents the type of measurable disease at enrollment: serum M-protein, urine M-protein, or difference between involved and uninvolved free light chain (dFLC).  
Note: Tumor burden at JNJ-68284528 infusion is based on the last non-missing value on or prior to the date of JNJ-68284528 infusion and after apheresis.  
Note: For subjects with measurable disease by serum M-protein and urine M-protein, the worst case scenario of change in tumor burden is presented i.e. the largest increase in tumor burden for subjects observed with increased tumor burden and the smallest decrease in tumor burden for subjects observed with decreased tumor burden.

FIG. 10




FIG. 11

| Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set<br>(Study 68284538MMY2001) |                   |                       |                                                                                                                                |                                            |                                                |                                                       |                                                        |                                   |                                          |                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------|-----------------------------------|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Site ID                                                                                                                       | Subject ID        | Age (years)/ Sex/Race | Line of Prior Therapy/<br>Year Since Diagnosis/<br>IES Staging at Study<br>Baseline/ SPO of EMP at<br>baseline if present (mm) | Worst<br>Toxicity<br>Grade of<br>CRS/ICONS | Preferred Term/<br>Requested Term              | Study Day of<br>AE<br>Onset/SAE<br>Duration<br>(days) | Toxicity<br>Grade of<br>Other<br>Neurotoxicity/<br>SAE | Outcome                           | Relationship to<br>Study<br>682845<br>28 | Medication/Procedure Given<br>(Start - End Day of<br>Medication/Procedure)                                                                                                                                                                                                                                                                                                     |
| US10012                                                                                                                       | 128US10<br>062023 | 68/65/White           | 6/3/5/2344                                                                                                                     | 3                                          | Extrapyramidal/<br>BRADYKINESIA                | 1015                                                  | 5N                                                     | Not<br>Recovered/<br>Not Resolved | Poss                                     |                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                               |                   |                       |                                                                                                                                |                                            | Micrographia/<br>MICROGRAPHIA                  | 1017                                                  | 5N                                                     | Not<br>Recovered/<br>Not Resolved | VL                                       |                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                               |                   |                       |                                                                                                                                |                                            | Parkinsonian/<br>PARKINSONIAN<br>LINE SYNDROME | 1015                                                  | 1Y                                                     | Not<br>Recovered/<br>Not Resolved | VL                                       | PLASMAPHERESIS (105 - 106)                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                               |                   |                       |                                                                                                                                |                                            | Reduced facial<br>expression/<br>HYPOMIMIA     | 1015                                                  | 1N                                                     | Not<br>Recovered/<br>Not Resolved | Poss                                     |                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                               |                   |                       |                                                                                                                                |                                            | Stoody/mixed/<br>BRADYKINESIA                  | 1051                                                  | 2N                                                     | Not<br>Recovered/<br>Not Resolved | Poss                                     |                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                               |                   |                       |                                                                                                                                |                                            | Parkinsonian/<br>PARKINSONIAN<br>LINE SYNDROME | 1051                                                  | 2Y                                                     | Not<br>Recovered/<br>Not Resolved | VL                                       | ANAKINRA [121 - 126];<br>ANAKINRA [127 - 137];<br>CARBOPALAEYDOPA [138<br>- 137]; ANAKINRA [137 - 137];<br>CARBOPALAEYDOPA [141<br>- 147]; IMMUNOGLOBULIN<br>HUMAN NORMAL [147 - 153];<br>CYCLOPHOSPHAMIDE [149 -<br>149]; CYTARABINE [149 - 149]<br>[HYDROCORTISONE [149 -<br>149]; CYCLOPHOSPHAMIDE<br>[155 - 156]; CYTARABINE [156<br>- 156]; HYDROCORTISONE<br>[156 - 156] |
|                                                                                                                               |                   |                       |                                                                                                                                |                                            | Reduced facial<br>expression/<br>HYPOMIMIA     | 1051                                                  | 2N                                                     | Not<br>Recovered/<br>Not Resolved | Poss                                     |                                                                                                                                                                                                                                                                                                                                                                                |

FIG. 12

| Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set<br>(Study 66284528NMV2001) |              |                       |                                                                                                     |                                  |                                                         |                                          |                                             |                                |                              |                                                                                                                                                                                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------------|-----------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------|------------------------------------------|---------------------------------------------|--------------------------------|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Site ID                                                                                                                       | Subject ID   | Age (years)/ Sex/Race | Line of Prior Therapy/<br>Year Since Diagnosis/<br>ISG Staging at Study/<br>Baseline T present (mm) | Worst Toxicity Grade of CRS/CANS | Preferred Term/<br>Reported Term                        | Study Day of AE Onset/AE Duration (days) | Toxicity Grade of Other Neurotoxicities/SAE | Outcome                        | Relationship to JNJ-56284528 | Medication/Procedure Given (Start - End Day of Medication/Procedure)                                                                                                                                                                                         |
| US10003                                                                                                                       | L29US1000011 | 58M/White             | 2/1.2/10                                                                                            | 2/1                              | Decreased level of consciousness/<br>MENTAL FIDGENSE    | 14                                       | 1N                                          | Recovered/<br>Not Resolved     | Poss                         |                                                                                                                                                                                                                                                              |
|                                                                                                                               |              |                       |                                                                                                     |                                  | Parkinsonism/<br>PARKINSONISM                           | 43/53                                    | 2N                                          | Not Recovered/<br>Not Resolved | Poss                         |                                                                                                                                                                                                                                                              |
|                                                                                                                               |              |                       |                                                                                                     |                                  | Tremor RIGID/<br>HAND TREMOR                            | 43                                       | 1N                                          | Not Recovered/<br>Not Resolved | Poss                         |                                                                                                                                                                                                                                                              |
|                                                                                                                               |              |                       |                                                                                                     |                                  | Flat affect/<br>FLAT AFFECT                             | 100                                      | 2N                                          | Not Recovered/<br>Not Resolved | Poss                         |                                                                                                                                                                                                                                                              |
|                                                                                                                               |              |                       |                                                                                                     |                                  | Memory impairment/<br>DIFFICULTY WITH SHORT TERM MEMORY | 100                                      | 2N                                          | Not Recovered/<br>Not Resolved | Poss                         |                                                                                                                                                                                                                                                              |
|                                                                                                                               |              |                       |                                                                                                     |                                  | Mental status changes/<br>ALTERED MENTAL STATUS         | 100/148                                  | 3P                                          | Not Recovered/<br>Not Resolved | Poss                         | DEXAMETHASONE [116 - 118] / DEXAMETHASONE [117 - 120] / DEXAMETHASONE [120 - 121] / DEXAMETHASONE [122 - 123] / DEXAMETHASONE [123 - 129] / DEXAMETHASONE [129 - 134] / DEXAMETHASONE [135 - 137] / DEXAMETHASONE [138 - 140] / CYCLOPHOSPHAMIDE [144 - 146] |
|                                                                                                                               |              |                       |                                                                                                     |                                  | Oral disturbance/<br>ORAL PRURITUS                      | 105                                      | 2N                                          | Not Recovered/<br>Not Resolved | Poss                         |                                                                                                                                                                                                                                                              |

FIG. 12 (continued)

| Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events: All Treated Analysis Set (Study 58284523MMY2061) |                |                       |                                                                                                  |                                   |                                           |                                          |                                             |                             |                               |                                                                                    |  |
|----------------------------------------------------------------------------------------------------------------------------|----------------|-----------------------|--------------------------------------------------------------------------------------------------|-----------------------------------|-------------------------------------------|------------------------------------------|---------------------------------------------|-----------------------------|-------------------------------|------------------------------------------------------------------------------------|--|
| Site ID                                                                                                                    | Subject ID     | Age (years); Sex/Race | Line of Prior Therapy; Year Since Diagnosis/ ISE (Staging at Study Baseline; if present (month)) | Worst Toxicity Grade of CRS/ICANS | Preferred Term/ Reported Term             | Study Day of AE Onset/AE Duration (days) | Toxicity Grade of Other Neurotoxicities/SAE | Outcome                     | Results ship to JJJ-582845 26 | Medication/Procedure Given (Start - End Day of Medication/Procedure)               |  |
|                                                                                                                            |                |                       |                                                                                                  |                                   | Micromedesis/ MICROGRAPHIA                | 105                                      | 2H                                          | Not Recovered/ Not Resolved | Pass                          |                                                                                    |  |
|                                                                                                                            |                |                       |                                                                                                  |                                   | Parkinsonism/ PARKINSONISM                | 105                                      | 3N                                          | Not Recovered/ Not Resolved | Pass                          |                                                                                    |  |
|                                                                                                                            |                |                       |                                                                                                  |                                   | Tremor/ LEFT HAND TREMOR                  | 105                                      | 1H                                          | Not Recovered/ Not Resolved | Pass                          |                                                                                    |  |
| US16017                                                                                                                    | LNUG510 017623 | 68/M/White            | 4-6.58                                                                                           | 2H                                | Personality change/ PERSONALITY CHANGE    | 100-5                                    | 3N                                          | Recovered/ Resolved         | VL                            | ALPRAZOLAM [108 - 109] / ALPRAZOLAM [109 - 110]                                    |  |
|                                                                                                                            |                |                       |                                                                                                  |                                   | Mood status changes/ ALTERED MENTATION    | 110-8                                    | 5Y                                          | Recovering/ Resolving       | VL                            | DEXAMETHASONE [110 - 113] / DEXAMETHASONE [113 - 115] / DEXAMETHASONE [115 - 118]  |  |
|                                                                                                                            |                |                       |                                                                                                  |                                   | Confusional state/ INTERMITTENT CONFUSION | 139-23                                   | 3Y                                          | Recovered/ Resolved         | Pass                          | HYDROCODONE [135 - 136] / METHOCTREXATE [136 - 137] / CYCLOPHOSPHAMIDE [137 - 138] |  |

FIG. 12 (continued)



| Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set<br>(Study 882845288MY2001) |            |                      |                                                                                                                                     |                                           |                                                  |                                                |                                                          |                        |                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------------------------------------------------------------------------------------------------|------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|--------------------------------------------------|------------------------------------------------|----------------------------------------------------------|------------------------|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Site ID                                                                                                                       | Subject ID | Age (years)/Sex/Race | Line of Prior Therapy/<br>Prior Event Diagnosis/<br>ISCT Staging of Study<br>Baseline/SPC of EIMP at<br>baseline/Pre-treatment (mm) | Neuro<br>Toxicity<br>Grade of<br>CRS/CNAs | Predetermined Term/<br>Reported Term             | Study Day of<br>AE Onset/AE<br>Duration (days) | Toxicity<br>Grade of<br>Other<br>Neurotoxicity<br>to SAE | Outcome                | Relationship to<br>SAE<br>R07845<br>289 | Medication/Procedure Given<br>(Start - End Day of<br>Medication/Procedure)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                               |            |                      |                                                                                                                                     |                                           | Motor dysfunction/<br>WEAK GRASP                 | 150/288                                        | 3N                                                       | Recovered/<br>Resolved | Prob                                    | DEXAMETHASONE [131 - 131]<br>/ DEXAMETHASONE [132 -<br>138] / METHOTREXATE [135 -<br>135] / CYCLOPHOSPHAMIDE<br>[136 - 135] /<br>DEXAMETHASONE [138 - 141]<br>/ DEXAMETHASONE [141 -<br>143] / DEXAMETHASONE [144<br>- 147] / DEXAMETHASONE<br>[148 - 148] /<br>DEXAMETHASONE [150 - 168]<br>/ DEXAMETHASONE [168 -<br>171] / DEXAMETHASONE [171<br>- 173] / DEXAMETHASONE<br>[173 - 175] /<br>DEXAMETHASONE [175 - 180]<br>/ DEXAMETHASONE [180 -<br>184] / DEXAMETHASONE [184<br>- 188] / DEXAMETHASONE<br>[188 - 187] /<br>DEXAMETHASONE [187 - 187]<br>/ DEXAMETHASONE [188 -<br>188] / DEXAMETHASONE [188<br>- 187] / DEXAMETHASONE<br>[187 - 203] /<br>DEXAMETHASONE [203 - 211]<br>/ DEXAMETHASONE [212 -<br>218] |
|                                                                                                                               |            |                      |                                                                                                                                     |                                           | Personality<br>change/<br>PERSONALITY<br>CHANGES | 182/17                                         | 3N                                                       | Recovered/<br>Resolved | VL                                      | DEXAMETHASONE [132 - 138]<br>/ DEXAMETHASONE [138 -<br>141] / DEXAMETHASONE [141<br>- 143]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

FIG. 12 (continued)

| Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set (Study 68284528MMY2001) |                |                       |                                                                                                                     |                                    |                                                    |                                          |                                             |                             |                              |                                                                      |
|----------------------------------------------------------------------------------------------------------------------------|----------------|-----------------------|---------------------------------------------------------------------------------------------------------------------|------------------------------------|----------------------------------------------------|------------------------------------------|---------------------------------------------|-----------------------------|------------------------------|----------------------------------------------------------------------|
| Site ID                                                                                                                    | Subject ID     | Age (years)/ Sex/Race | Line of Prior Therapy/ Year Since Diagnosis/ ISS Staging at Study Baseline/ SPD at EMP at baseline & present (mm/s) | Worst Toxicity Grade of ONSET/CAUS | Predetermined Term/ Reported Term                  | Study Day of AE Onset/AE Duration (days) | Toxicity Grade of Other Neurotoxicities/SAE | Outcome                     | Relationship to JNJ-68284528 | Medication/Procedure Given (Start - End Day of Medication/Procedure) |
|                                                                                                                            |                |                       |                                                                                                                     |                                    | Personality change/ PERSONALITY CHANGES            | 1584                                     | 3N                                          | Recovered/ Resolved         | YL                           | DEXAMETHASONE [168 - 171]                                            |
|                                                                                                                            |                |                       |                                                                                                                     |                                    | Stereotypy/ REPETITIVE MOVEMENTS                   | 1682                                     | 3N                                          | Recovered/ Resolved         | YL                           | DEXAMETHASONE [168 - 171]                                            |
| US18024                                                                                                                    | 128UG10 921965 | 77M/White             | 19/5 NW                                                                                                             | 2+1                                | Tremor/ BILATERAL HAND TREMOR                      | 27/95                                    | 1N                                          | Recovered/ Resolved         | Poss                         |                                                                      |
|                                                                                                                            |                |                       |                                                                                                                     |                                    | Carpal tunnel rigidity/ UPPER EXTREMITIES          | 29/16                                    | 2N                                          | Recovering/ Resolving       | Poss                         |                                                                      |
|                                                                                                                            |                |                       |                                                                                                                     |                                    | Parkinsonism/ PARKINSONIAN FEATURES                | 29/29                                    | 3Y                                          | Recovering/ Resolving       | Poss                         |                                                                      |
|                                                                                                                            |                |                       |                                                                                                                     |                                    | Bradykinesia/ BRADYKINETIC                         | 43/93                                    | 1N                                          | Recovered/ Resolved         | Poss                         |                                                                      |
|                                                                                                                            |                |                       |                                                                                                                     |                                    | Carpal tunnel rigidity/ UPPER EXTREMITIES          | 43/96                                    | 1N                                          | Recovered/ Resolved         | Poss                         |                                                                      |
|                                                                                                                            |                |                       |                                                                                                                     |                                    | Gait disturbance/ GAIT SLOWED                      | 43/                                      | 1N                                          | Not Recovered/ Not Resolved | Poss                         |                                                                      |
|                                                                                                                            |                |                       |                                                                                                                     |                                    | Micrographia/ MICROGRAPHIA                         | 48/93                                    | 1N                                          | Recovered/ Resolved         | Poss                         |                                                                      |
|                                                                                                                            |                |                       |                                                                                                                     |                                    | Posture abnormal/ STOOPED POSTURE                  | 43/146                                   | 1N                                          | Not Recovered/ Not Resolved | Poss                         |                                                                      |
|                                                                                                                            |                |                       |                                                                                                                     |                                    | Psychomotor retardation/ SLOW PSYCHOMOTOR FUNCTION | 43/                                      | 1N                                          | Not Recovered/ Not Resolved | Poss                         |                                                                      |

FIG. 12 (continued)

| Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set<br>(Study 68284528MMY2001) |                  |                       |                                                                                                                    |                                  |                                                                             |                                          |                                              |                                   |                                |                                                                      |
|-------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------|------------------------------------------|----------------------------------------------|-----------------------------------|--------------------------------|----------------------------------------------------------------------|
| Site ID                                                                                                                       | Subject ID       | Age (years)/ Sex/Race | Line of Prior Therapy/ Year Since Diagnosis/ ISE Staging at Study Baseline/ SPD of EMP at baseline if present (mm) | Worst Toxicity Grade of CRSICANS | Preferred Term/ Reported Term                                               | Study Day of AE Onset/AE Duration (days) | Toxicity Grade of Other Neurotoxicity as SAE | Outcome                           | Relationship to Study 68284528 | Medication/Procedure Given (Start - End Day of Medication/Procedure) |
|                                                                                                                               |                  |                       |                                                                                                                    |                                  | Parkinsonian/ PARKINSONIAN FEATURES                                         | 56                                       | 1/Y                                          | Not Recovered/ Not Resolved       | Poss                           |                                                                      |
|                                                                                                                               |                  |                       |                                                                                                                    |                                  | Posture abnormal/ STICKED POSTURE                                           | 36/5                                     | 1/N                                          | Not Recovered/ Not Resolved       | Poss                           |                                                                      |
|                                                                                                                               |                  |                       |                                                                                                                    |                                  | Reduced facial expressions/ MASKLIKE FACE                                   | 36/5                                     | 1/N                                          | Not Recovered/ Not Resolved       | Poss                           |                                                                      |
| US10025                                                                                                                       | L281513 / 025003 | 62/M/White            | 9/7.3/0                                                                                                            | 2/Y                              | Micrographia/ MICROGRAPHIA                                                  | 12/15                                    | 1/N                                          | Not Recovered/ Not Resolved       | VL                             |                                                                      |
|                                                                                                                               |                  |                       |                                                                                                                    |                                  | Parkinsonian/ NERVOUS SYSTEM DISORDERS OTHER - PARKINSON'S DISEASE SYNDROME | 18/12                                    | 1/N                                          | Recovered/ Resolved With Sequelae | Poss                           | DEXAMETHASONE [22 - 30] / OXYGEN [72 - 110]                          |
|                                                                                                                               |                  |                       |                                                                                                                    |                                  | Micrographia/ MICROGRAPHIA WORSEN                                           | 30                                       | 2/N                                          | Not Recovered/ Not Resolved       | VL                             |                                                                      |

FIG. 12 (continued)

| Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events, All Treated Analysis Set<br>(Study 68264328MMY2001) |            |                       |                                                                                                                                   |                                            |                                                                                           |                                                   |                                                       |                                   |                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------|-------------------------------------------------------|-----------------------------------|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Site ID                                                                                                                       | Subject ID | Age (years/ Sex/Race) | Line of Prior Therapy/<br>Year Since Diagnosis/<br>ISS Staging at Study<br>Baseline/ SPD of EMP at<br>Baseline if present (prior) | Worst<br>Toxicity<br>Grade of<br>CRS/ICANS | Preferred Term/<br>Reported Term                                                          | Study Day of<br>AE<br>Onset/AE<br>Duration (days) | Toxicity<br>Grade of<br>Other<br>Neurotoxic<br>eae/AE | Outcome                           | Relation to<br>JNJ-<br>66284328 | Medication/Procedure Given:<br>Start - End Day of<br>Medication/Procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                               |            |                       |                                                                                                                                   |                                            | Parkinson's/<br>NERVOUS<br>SYSTEM<br>DISORDER-<br>OTHER<br>PARKINSONS<br>LIKE<br>SYNDROME | 33                                                | 3Y                                                    | Not<br>Recovered/<br>Not Resolved | Prob                            | DEXAMETHASONE (22 - 30) /<br>DEXAMETHASONE (30 - 47) /<br>CARBOPOL/LEVODOPA (37 -<br>102) / DEXAMETHASONE (48 -<br>52) / CYCLOPHOSPHAMIDE<br>(52 - 52) / DEXAMETHASONE<br>(52 - 52) / CYTARABINE (53 -<br>53) / HYDROCORTISONE (55 -<br>53) / DEXAMETHASONE (53 -<br>55) / DEXAMETHASONE (55 -<br>57) / GILTUXIMAB (57 - 57) /<br>DEXAMETHASONE (57 - 58) /<br>DEXAMETHASONE (58 - 61) /<br>HYDROCORTISONE (61 - 61) /<br>METHYLPREDNISONE (61 - 61) /<br>DEXAMETHASONE (61 - 102) /<br>LEVETIRACETAM (64 - 64) /<br>LEVETIRACETAM (64 - 64) /<br>DASATINIB (65 - 67) /<br>DASATINIB (73 - 76) /<br>ANAKINRA (76 - 82) /<br>DASATINIB (76 - 107) /<br>ANAKINRA (86 - 102) |
|                                                                                                                               |            |                       |                                                                                                                                   |                                            | Reduced facial<br>expressions/<br>MASKED FACES                                            | 33                                                | 1Y                                                    | Not<br>Recovered/<br>Not Resolved | Prob                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                               |            |                       |                                                                                                                                   |                                            | Memory<br>impairment/<br>MEMORY<br>IMPAIRMENT                                             | 37                                                | 4Y                                                    | Not<br>Recovered/<br>Not Resolved | Prob                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

FIG. 12 (continued)

| Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events: All Treated Analysis Set<br>(Study 682643288MY2301)                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |                       |                                                                                                                                    |                                           |                                  |                                                |                                                        |         |                                 |                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|----------------------------------|------------------------------------------------|--------------------------------------------------------|---------|---------------------------------|----------------------------------------------------------------------------|
| Site ID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Subject ID | Age (years)/ Sex/Race | Line of Prior Therapy/<br>Year Since Diagnosis/<br>ISL: Staging at Study<br>Baseline/ EPS of EAP at<br>baseline: if present (pre?) | Worst<br>Toxicity<br>Grade of<br>CRS/CANS | Preferred Term/<br>Reported Term | Study Day of<br>AE Onset/AE<br>Duration (days) | Toxicity<br>Grade of<br>Other<br>Neurotoxicity/<br>SAE | Outcome | Relationship<br>to JNJ-68264328 | Medication/Procedure Given<br>[Start - End Day of<br>Medication/Procedure] |
| <p>Key: AE = adverse event, CRS = cytokine release syndrome, DO = duration, EAP = extramedullary plasmacytoma, ICARIS = Immune Effector Cell-Associated Neurotoxicity, NR = not related, Poss = possible, Prob = probable, SAE = serious adverse event, EPS = sum of product of diameters, VL = very likely</p> <p>* Study day of AE onset is in reference to the initial administration of JNJ-68264328 (Day 1).</p> <p>* Relationship to JNJ-68264328 is assessed by the investigator.</p> <p>Note: Adverse events are coded using MedDRA Version 25.0.</p> |            |                       |                                                                                                                                    |                                           |                                  |                                                |                                                        |         |                                 |                                                                            |

FIG. 12 (continued)






FIG. 13

**FIG. 14**

**FIG. 15**